News
-
-
-
COMMUNIQUÉ DE PRESSE
Jaguar Health Announces First Patient Dosed in Investigator-Initiated Trial (IIT) Evaluating Crofelemer for the Rare Disease Indication of Microvillus Inclusion Disease (MVID), with Proof-of-Concept (POC) Data Potentially Available H1 2025
Sheikh Khalifa Medical City hosts Jaguar Health's crofelemer trial for MVID & SBS-IF. POC data aims to support early patient access in EU countries -
-
-
-
-
-
COMMUNIQUÉ DE PRESSE
Jaguar Health Presenting January 13 at Lytham 2025 Investor Healthcare Summit & January 14 at Biotech Showcase
Jaguar Health, Inc. to participate in virtual fireside chat and in-person presentation at upcoming healthcare events. Focus on developing medicines from rainforest plants -
